Skip to main content

Table 1 Baseline characteristics for the study population

From: Social factors and age play a significant role in cervical cancer and advanced-stage disease among Danish women

 

Total study population1 (n = 72,913)

Sub-grouped study population with known disease stage (n = 67,025)

Low-stage subpopulation2 (n = 36,744)

High-stage subpopulation3 (n = 30,281)

Cases (n = 12,160)

Controls (n = 60,753)

Cases (n = 6,126)

Controls (n = 30,618)

Cases (n = 5,050)

Controls (25,231)

Age

    

**

**

 < 35

 35–44

 45–54

 55–64

 65–74

 > 75

1,996 (16.4%)

2,856 (23.5%)

2,148 (17.7%)

1,842 (15.2%)

1,758 (14.5%)

1,760 (12.8%)

9,964 (16.4%)

14,288 (23.5%)

10,745 (17.7%)

9,208 (15.2%)

8,774 (14.4%)

7,774 (12.8%)

1,489 (24.3%)

1,955 (31.9%)

1,136 (18.5%)

733 (12.0%)

542 (8.9%)

271 (4.4%)

7,433 (24.3%)

9,780 (31.9%)

5,685 (18.6%)

3,667 (12.0%)

2,700 (8.8%)

1,353 (4.4%)

356 (7.1%)

710 (14.1%)

872 (17.3%)

1,003 (19.9%)

1,056 (20.9%)

1,053 (20.9%)

1,776 (7.0%)

3,553 (14.1%)

4,362 (17.3%)

5,010 (19.9%)

5,277 (20.9%)

5,253 (20.8%)

Cohort

    

**

**

 1987–1992

 1993–1998

 1999–2004

 2005–2010

 2011–2016

2,974 (24.5%)

2,578 (21.2%)

2,205 (18.1%)

2,206 (18.1%)

2,197 (18.1%)

14,858 (24.5%)

12,882 (21.2%)

11,012 (18.1%)

11,020 (18.1%)

10,981 (18.1%)

1,618 (26.4%)

1,253 (20.5%)

1,079 (17.6%)

1,048 (17.1%)

1,128 (18.4%)

8,088 (26.4%)

6,262 (20.5%)

5,389 (17.6%)

5,239 (17.1%)

5,640 (18.4%)

1,224 (24.2%)

1,159 (22.9%)

940 (18.6%)

937 (18.6%)

790 (15.6%)

6,116 (24.2%)

5,791 (22.9%)

4,694 (18.6%)

4,681 (18.6%)

3,949 (15.6%)

Education

 

*

 

*

**

**, *

 Short

 Medium

 High

 Unknown

4,517 (37.2%)

4,010 (32.9%)

2,230 (18.3%)

1,403 (11.5%)

19,089 (31.4%)

20,911 (34.4%)

13,489 (22.2%)

7,264 (12.0%)

1,946 (31.8%)

2,350 (38.4%)

1,489 (24.3%)

341 (5.6%)

8,675 (28.3%)

11.779 (38.5%)

8,121 (26.5%)

2,043 (6.7%)

2,233 (44.2%)

1.340 (26.5%)

584 (11.6%)

893 7.7%)

8,881 (35.2%)

7.556 (29.9%)

4,365 (17.3%)

4,429 (17.6%)

Comorbidity

    

**

**

 CCI = 0

 CCI = 1

 CCI = 2

 CCI > 2

10,265(84.4%)

956 (7.9%)

650 (5.4%)

289 (2.4%)

51,793(85.3%)

4,601 (7.6%)

3,071 (5.1%)

1,288 (2.1%)

5,461 (89.1%)

355 (5.8%)

231 (3.8%)

79 (1.3%)

27,364 (89.4%)

1,718 (5.6%)

1,128 (3.7%)

408 (1.3%)

4,075 (80.7%)

507 (10.0%)

327 (6.5%)

141 (2.8%)

20,515 (81.3%)

2,390 (9.5%)

1,615 (6.4%)

711 (2.8%)

Working status

 

*

 

*

**

**, *

 Working

 Senior

 Other

 Unknown

5,867 (48.3%)

4,608 (37.9%)

1,677 (13.8%)

8 (0.1%)

31,546 (51.9%)

21,361 (35.2%)

7,226 (11.9%)

620 (1.0%)

3,824 (62.4%)

1,327 (21.7%)

973 (15.9%)

(0%)

19,493 (63.7%)

6,249 (20.4%)

4.533 (14.8%)

343 (1.1%)

1,648 (32.6%)

2,809 (55.6%)

592 (11.7%)

(0%)

9,912 (39.3%)

12,858 (51.0%)

2,231 (8.8%)

230(1%)

Socio-economic status

 

*

 

*

**

**, *

 Low

 High

 Unknown

6,555 (53.9%)

3,776 (31.1%)

1,829 (15.0%)

32,863 (54.1%)

23,338 (38.4%)

4,552 (7.5%)

3,171 (51.8%)

2,335 (38.1%)

620 (10.1%)

15,355 (50.2%)

12,665 (41.4%)

2,598 (8.5%)

2,865 (56.6%)

1,203 (23.8%)

982 (19.5%)

14,560 (57.7%)

9,070 (36.0%)

1,601 (6.4%)

Civil status

 

*

 

*

**

**, *

 Living alone

 Living with a partner

 Unknown

4,613 (37.9%)

7,482 (61.5%)

65 (0.5%)

18,984 (31.3%)

40.993 (67.5%)

776 (1.3%)

1,919 (31.3%)

4,179 (68.2%)

28 (0.5%)

7,954 (26.0%)

22,210 (72.5%)

454 (1.5%)

2,256 (44.7%)

2,768 (54.8%)

30 (0.5%)

9,217 (36.5%)

15,751 (62.4%)

263 (1.0%)

Born in Denmark

 

*

 

*

 

**

 Yes

 No

11,132 (91.6%)

1,028 (8.5%)

54,752 (90.1%)

6,001 (9.9%)

5,601 (91.4%)

525 (8.6%)

27,246 (89.0%)

3,372 (11.0%)

4,629 (91.7%)

421 (8.3%)

23,050 (91.4%)

2,181 (8.6%)

  1. 1 Total study population includes all women diagnosed with CC between 1987 and 2016, i.e., women with unknown stage of CC and matched controls are also included in this population
  2. 2 Low-stage subpopulation includes women diagnosed with early-stage CC (FIGO IA-IB2) between 1987 and 2016 and these women’s age- and residence-matched women from the overall control group
  3. 3 High-stage subpopulation includes women diagnosed with advanced stage CC (FIGO IIA+) between 1987 and 2016 and these women’s age- and residence-matched women from the overall control group
  4. * Comparison between total cases vs. total controls, low-stage cases vs. low-stage controls, and high-stage cases vs. high-stage controls. χ²-test with 0.05 significance level
  5. ** Comparisons between low-stage cases vs. high-stage cases. χ²-test with 0.05 significance level
  6. * Comparison between cases vs. controls P < 0.05
  7. ** Comparisons between low-stage cases vs. high-stage cases. P < 0.05
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us